MTOR and pulmonary arterial hypertension: Following twice a week administration of RAP NPs at the time of PAH induction for a duration of 4 weeks, RAP NPs significantly reduced pulmonary arteriole hypertrophy (Figures 5A,B) and RV ventricular remodeling compared to vehicle controls, and prevented increases in right ventricular systolic pressures and phosphorylation of S6, a downstream effector of mTOR.